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Oral Presentations S183numbers of UCB cells, including T cells. We evaluated the feasi-
bility of generating UCB-derived CD19-specific T cells for clinical
infusion from the T cells in this residual. These T cells were elec-
troporated with CD19RCD28 CAR expressed as a Sleeping Beauty
(SB) transposon and propagated in the presence of IL-2 and IL-21
on g-irradiated CD19+ K562 artificial antigen presenting cells
(aAPC). The electroporated and propagated cells were a population
of CD8+ and CD4+ memory and effector T cells that exhibit
redirected CD19-dependent killing and cytokine production. The
UCB-derived CD19-specific T cells were further analyzed using
a new technology using the NanoString nCounter Analysis System,
a digital technology that is based on direct multiplexed measure-
ment of mRNA and therefore gene expression that offers a high
level of precision and sensitivity from a few number of cells.
This approach to manufacturing CD19-specific T cells and analy-
sis of mRNA expression profiles will be used to generate donor-
derived CD19-specific T cells that can be infused after UCBT as
an approach to enhance the graft-versus-tumor-effect without
increasing GvHD. The relative ease and low cost associated with
production of clinical grade DNA plasmids, electroporation, and
reproducible outgrowth of T cells stablely expressing CAR on
thawed g-irradiated MCB of aAPC, should enable facilities operat-
ing in compliance with cGMP for Phase I/II to implement adop-
tive immunotherapy trials using CAR+ T cells. By using the
scant numbers of residual UCB cells present after washing, we
have identified one potential way to overcome a major barrier to
UCB-derived T-cell therapies.75
IMPACT OF DONOR CHOICE ON PEDIATRIC DAY +100 TRANSPLANT
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Indianapolis, INBackground: A genotypically matched sibling is almost universally
the preferred donor source for pediatric patients undergoing alloge-
neic hematopoietic stem cell transplant (HSCT). Some patients lack-
ing a matched sibling donor will have a matched or mismatched
related donor identified. It is not clear whether in this setting a family
donor is preferable to an unrelated donor. Using the data base of the
Pediatric BoneMarrow Transplant Consortium from 2002-2004 we
evaluated 100 daymortality in 2696 patients\22 years of age receiv-
ing an non-syngeneic HSCT.
Results: The observed 100 day mortality for matched sibling do-
nors (n5 624) was 9.5%, for other matched family donors (n5 41)
12% and for mismatched sibling donors (n5 89) 19%. Univariate
analysis assigning a value of 1 for the 100 day mortality reported
for 939 autologous transplants from this cohort was performed.
There was no difference in mortality seen in patients transplanted
from amatched sibling donor (OR5 1.2,NS) or othermatched fam-
ily donor (OR5 1.6, NS). The use ofmismatched sibling donors and
matched or mismatched unrelated donors resulted in a significant in-
crease in Day 100 mortality (OR5 2.8-4.1, p\0.005). However, in
multivariate analysis incorporating 47 independent variables there
was a trend toward increased mortality as donor disparity increased.
Compared to those undergoing autologous transplant, patients re-
ceiving a transplant from a matched sibling donor had an OR of
2.3 (95% CI, 1.2-4.5), other matched family donor 3.6 (95% CI,
1.2-11.3), mismatched sibling donor 4.5 (95% CI, 2-10.2), matched
unrelated donor 6.4 (95% CI, 3.9-16.6) and mismatched unrelated
donor 7.8 (95% CI, 3-14.5).
Conclusion: When an HLA matched sibling donor is not avail-
able, the differences in acute mortality between alternative donor
options may be outweighed by other donor/patient considerations.
The use of a mismatched sibling donor or unrelated donor com-
pared to a matched family donor may confer an increased risk
that should be considered in the context of individual patient
circumstances.76
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A number of reports document the successful role of matched
related donor hematopoietic stem cell transplant (MRDHSCT)
in patients with Chronic Granulomatous Disease (CGD). Less cer-
tain is the safety and efficacy of HSCT from unrelated donors. We
report the use of HSCT in ten children with a matched related do-
nor (MRD) (n5 4) or a matched unrelated donor (MUD) (n5 6).
The median age of our group was 4.7 years (range: 0.9-8.4 years)
with x-linked (n5 8) or autosomal recessive (n5 2) disease over
a 6 year period (2003-2009). Despite treatment with anti-bacterial
and anti-fungal medications and gamma interferon, nine children
had significant clinical infections before transplant including: oste-
omyelitis (n5 2), lung/liver abscess requiring surgical intervention
(n5 3), aspergillus pneumonia (n5 3) and staphylococcus/
B.cepaciae sepsis/shock (n5 2). The conditioning regimen for pa-
tients receiving a MRD product consisted of busulfan(1 mg/kg,
AUC 900 – 1200 mmol/min/L), cyclophosphamide(90 mg/kg) and
cytarabine(2grams/m2). Patients receiving a MUD product were
conditioned with busulfan(1 mg/kg, AUC 900 – 1200 mmol/min/
L), cychlophosphamide(200 mg/kg) and fludarabine(120 mg/m2).
GvHD prophylaxis consisted of cyclosporine and methrotrexate
for MUD recipients and cyclosporine and prednisone for MRD re-
cipients. Campath (anti-CD52) was used to improve engraftment
and prevent aGvHD in all the patients. The median total nucleated
cell dose was 6108/kg. The median time to neutrophil and plate-
let recovery was 18 days (range, 12-40 days) and 16 days (range, 12-
26 days) respectively. The majority of the patients (n5 8) achieved
100% neutrophil engraftment except two (68, 73%) but all have
sustained correction of their neutrophil oxidative burst defect.
Four patients developed grade I aGVHD requiring only topical
treatment. None of the patients developed grade II-IV aGvHD.
There has been no incidence of cGvHD. Among the post trans-
plant morbidities we report: busulfan related seizures (n5 1), BK
hemorrhagic cystitis (n5 1), and bacterial/fungal pneumonia
(n5 2). None of the patients developed organ failure during the
post transplant period. All patients are currently living with follow
up ranging from 42 days to 6 years. In our cohort, the outcome of
MUDSCT is very feasible and equivalent to MRDSCT and should
be considered early in the course of CGD to cure the underlying
neutrophil defect and improve quality of life in the absence of
a MRD.77
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Reduced intensity conditioning (RIC) enables SCT in children
with pre-existing organ toxicity. However, there are concerns about
mixed chimerism(MC) in the long term that is sometimes not
sufficient for cure. In a cohort of 148 patients undergoing RIC
SCT (Fludarabine 150 mg/m2, Melphalan 140 mg/m2, Campath
1H 0.6-1 mg/kg) we compared chimerism between those who re-
ceived BM (n5 109) Vs PBSC (n5 41). Median age at transplant
was 3.6 years and median follow-up was 4.7 years.The majority
were transplanted for primary immunodeficiency disorders
(n5 120) and donors were MUD (n5 67), mMUD (n5 45), MSD
(n5 17),MFD (n5 14) andmMFD (n5 8). Survival was equivalent,
70% for BMand 75% for PBSC. Incidence of aGVHD$ grade 2 was
higher with PBSC (40% vs 20% for BM) but the incidence of chronic
GVHD was low (10%).
